Best peptides for fat loss

Investigational once-weekly fixed combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, studied in the Phase 3 REDEFINE program for weight management.

• Substantial weight loss in Phase 3 trials (about 20% at week 68 in REDEFINE 1)
• Greater weight loss than either component alone in the pivotal trial

The GLP-1 pioneer for sustainable weight loss and cardiovascular health.

• Significant weight loss
• Strong appetite suppression

FDA-approved GLP-2 analog that promotes intestinal mucosal growth and absorption, used for short bowel syndrome in patients dependent on parenteral support.

• Increases intestinal villus height and crypt depth, improving absorption
• Reduces dependence on parenteral nutrition and IV fluids in short bowel syndrome
• Approved for both adult and pediatric short bowel syndrome

Trims visceral fat while boosting IGF-1 levels, great for shredded longevity looks.

• Reduces visceral fat

Weight & Glucose Manager.

• Weight loss
• Appetite suppression

Amylin analog co-developed with semaglutide as 'CagriSema' for next-gen weight loss.

• Augments GLP-1 weight loss

Stronger ghrelin-mimetic than GHRP-6; releases GH with milder appetite spike.

• GH release
• Lean mass support
• Less hunger than GHRP-6

Growth Mediator.

• Fat loss

Gentle GH releaser that amps muscle growth and fat loss without the harsh sides.

• Accelerates fat loss

Oral GH secretagogue that cranks appetite, muscle preservation, and bone density.

• Increases muscle mass
• Improves bone density
• Improves sleep quality

The 'Godzilla' of weight loss; a triple-hormone agonist for unprecedented fat loss and metabolic health.

• Unrivaled weight loss (up to 24%+)
• Reverses liver fat (80%+ reduction)
• Reduces visceral fat

Mimics natural GH pulses to build lean mass and improve sleep/recovery.

• Reduces body fat

GH Stimulator.

• Increases appetite

Potent tanning and libido enhancement.

• Appetite suppression

An investigational proapoptotic peptidomimetic that targets the blood supply of white fat; it produced weight loss in obese primates but caused reversible kidney effects, and human data are limited to a single early-phase safety study.

• Preclinical: targeted destruction of white-fat vasculature causing fat loss
• Preclinical: weight loss and improved insulin resistance in obese monkeys
• Mechanistically distinct from appetite-based fat-loss agents

Potent GH stimulator for quick strength gains and vascularity in bodybuilders.

• Fat loss

Fat Loss Peptide without the growth effects.

• Fat loss
• Inhibits fatty acid formation

Mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity.

• Boosts metabolism

Investigational small-molecule ERR (estrogen-related receptor) agonist studied preclinically as an exercise mimetic. Mouse data only; no human studies. Educational use only.

• Preclinical: reduced fat mass and improved insulin sensitivity in obese mouse models

Investigational community stack pairing a triple incretin agonist with a long-acting amylin analog.

• Enhanced satiety via dual incretin + amylin pathways
• Reduced visceral and hepatic fat (retatrutide component data)

Small-molecule NNMT inhibitor that boosts NAD+ and white-fat mobilization.

• Lipolysis support

Weekly GLP-1 agonist fused to albumin; discontinued GSK product (Tanzeum/Eperzan).

• Weekly dosing
• HbA1c reduction
• CV benefit (HARMONY)

Oral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.

• Improves appetite

Modified HGH fragment 176-191 analog targeted at fat loss without GH side effects.

• Targets stubborn fat
• Stimulates lipolysis

Russian actoprotectant adamantane; mild dopaminergic stimulant approved for asthenia.

• Anti-fatigue without classical stimulant comedown

Oral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.

• Stimulates appetite

Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.

• Once-weekly dosing
• HbA1c reduction
• CV risk reduction (REWIND)

First-in-class GLP-1 mimetic derived from Gila monster venom; sold as Byetta/Bydureon.

• Modest weight loss

Growth Hormone Essentials.

• Fat loss

Mitochondrial-derived peptide that protects against amyloid-beta and metabolic stress.

• Neuroprotection vs amyloid-beta
• Insulin sensitization
• Cytoprotective in mitochondrial stress

Investigational blend pairing a clean GHRP (ipamorelin) with a stable GHRH (tesamorelin).

• Visceral fat targeting via tesamorelin

Daily GLP-1 analog; FDA-approved for diabetes (Victoza) and obesity (Saxenda®).

• Weight loss ~5-8%

Short-acting prandial GLP-1 agonist; sold as Adlyxin/Lyxumia by Sanofi.

• Modest weight loss

GLP-1 / glucagon dual agonist (Innovent / Eli Lilly) submitted in China for obesity 2024.

• Weight loss with energy expenditure boost
• Hepatic fat reduction

First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.

• Weight loss comparable to injectable GLP-1s in Phase 2

Investigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.

• Strong weight loss (~19% Phase 2)
• MASH liver-fat reduction

Triple monoamine reuptake inhibitor with strong weight-loss data; not FDA-approved.

• Significant weight loss
• Appetite suppression

Tesofensine paired with metoprolol (Tesomet) to control HR while preserving weight loss.

• Preserves weight loss
• Studied in Prader-Willi and hypothalamic obesity